论文部分内容阅读
目的研究Rho激酶特异性抑制剂Y-27632对人肝癌HepG2细胞增殖的抑制作用。方法体外培养人肝癌HepG2细胞,分为正常对照组(C组)以及不同浓度Y-27632 2.5、5、10、25、50μmol/L处理组(分别为A1组、A2组、A3组、A4组、A5组)。镜下观察HepG2细胞的生长变化,MTT法检测各组HepG2细胞增殖情况。结果在Y-27632作用下,HepG2细胞失去原有“铺路石”样排列,细胞间连接减少,细胞间隙增大,细胞胞体皱缩、变圆,细胞黏附性下降,有倾向凋亡趋势。与C组相比,不同浓度Y-27632作用后的HepG2细胞光密度值减少,细胞活力相对下降,且呈浓度依赖性(P<0.05)。结论 Rho激酶抑制剂Y-27632能有效抑制人肝癌HepG2细胞增殖。
Objective To study the inhibitory effect of Rho kinase-specific inhibitor Y-27632 on the proliferation of HepG2 cells. Methods HepG2 cells were cultured in vitro and divided into normal control group (C group) and different concentrations of Y-27632 2.5, 5, 10, 25 and 50μmol / L treatment groups (A1, A2, A3 and A4 , A5 group). The growth of HepG2 cells was observed under microscope, and the proliferation of HepG2 cells was detected by MTT assay. Results Under the action of Y-27632, HepG2 cells lost the original arrangement of “paving stones”, the number of intercellular junctions decreased, the number of intercellular spaces increased, cell bodies shrank and rounded, cell adhesion decreased, and tended to be apoptotic . Compared with group C, HepG2 cells treated with different concentrations of Y-27632 showed a decrease in optical density and a relative decrease in cell viability in a concentration-dependent manner (P <0.05). Conclusion Rho kinase inhibitor Y-27632 can effectively inhibit the proliferation of HepG2 cells.